Pathological evaluation of tumor tissue is pivotal for diagnosis in cancer patients and automated image analysis approaches have great potential to increase precision of diagnosis and help reduce human error. In this study, we utilize several computational methods based on convolutional neural networks (CNN) and build a stand-alone pipeline to effectively classify different histopathology images across different types of cancer. In particular, we demonstrate the utility of our pipeline to discriminate between two subtypes of lung cancer, four biomarkers of bladder cancer, and five biomarkers of breast cancer. In addition, we apply our pipeline to discriminate among four immunohistochemistry (IHC) staining scores of bladder and breast cancers. Our classification pipeline includes a basic CNN architecture, Google's Inceptions with three training strategies, and an ensemble of two state-of-the-art algorithms, Inception and ResNet. Training strategies include training the last layer of Google's Inceptions, training the network from scratch, and fine-tunning the parameters for our data using two pre-trained version of Google's Inception architectures, Inception-V1 and Inception-V3. We demonstrate the power of deep learning approaches for identifying cancer subtypes, and the robustness of Google's Inceptions even in presence of extensive tumor heterogeneity. On average, our pipeline achieved accuracies of 100%, 92%, 95%, and 69% for discrimination of various cancer tissues, subtypes, biomarkers, and scores, respectively. Our pipeline and related documentation is freely available at https://github.com/ih-_lab/CNN_Smoothie.

Background: A definitive diagnosis of prostate cancer requires a biopsy to obtain tissue for pathologic analysis, but this is an invasive procedure and is associated with complications.Purpose: To develop an artificial intelligence (AI)‐based model (named AI‐biopsy) for the early diagnosis of prostate cancer using magnetic resonance (MR) images labeled with histopathology information.Study Type: Retrospective.Population: Magnetic resonance imaging (MRI) data sets from 400 patients with suspected prostate cancer and with histological data (228 acquired in‐house and 172 from external publicly available databases).Field Strength/Sequence: 1.5 to 3.0 Tesla, T2‐weighted image pulse sequences.Assessment: MR images reviewed and selected by two radiologists (with 6 and 17 years of experience). The patient images were labeled with prostate biopsy including Gleason Score (6 to 10) or Grade Group (1 to 5) and reviewed by one pathologist (with 15 years of experience). Deep learning models were developed to distinguish 1) benign from cancerous tumor and 2) high‐risk tumor from low‐risk tumor.Statistical Tests: To evaluate our models, we calculated negative predictive value, positive predictive value, specificity, sensitivity, and accuracy. We also calculated areas under the receiver operating characteristic (ROC) curves (AUCs) and Cohen's kappa.Results: Our computational method (https://github.com/ih-lab/AI-biopsy) achieved AUCs of 0.89 (95% confidence interval [CI]: [0.86–0.92]) and 0.78 (95% CI: [0.74–0.82]) to classify cancer vs. benign and high‐ vs. low‐risk of prostate disease, respectively.Data Conclusion: AI‐biopsy provided a data‐driven and reproducible way to assess cancer risk from MR images and a personalized strategy to potentially reduce the number of unnecessary biopsies. AI‐biopsy highlighted the regions of MR images that contained the predictive features the algorithm used for diagnosis using the class activation map method. It is a fully automatic method with a drag‐and‐drop web interface (https://ai-biopsy.eipm-research.org) that allows radiologists to review AI‐assessed MR images in real time.Level of Evidence: 1Technical Efficacy Stage: 2

The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image analysis, diagnosis, and treatment planning. AI techniques provide standardized assistance to clinicians, in which many diagnostic and predictive tasks are manually conducted, causing low reproducibility. These AI methods can additionally provide explainability to help clinicians make the best decisions for patient care. This review explores state-of-the-art AI methods, focusing on their application in image classification, image segmentation, multiple instance learning, generative models, and self-supervised learning. In radiology, AI enhances tumor detection, diagnosis, and treatment planning through advanced imaging modalities and real-time applications. In pathology, AI-driven image analysis improves cancer detection, biomarker discovery, and diagnostic consistency. Multimodal AI approaches can integrate data from radiology, pathology, and genomics to provide comprehensive diagnostic insights. Emerging trends, challenges, and future directions in AI-driven cancer research are discussed, emphasizing the transformative potential of these technologies in improving patient outcomes and advancing cancer care. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.